TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report published on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a neutral rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

Check Out Our Latest Stock Report on TRACON Pharmaceuticals

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.07 on Friday. The company has a market cap of $242,792.00, a P/E ratio of 0.02 and a beta of 1.36. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The firm has a 50-day simple moving average of $0.11 and a two-hundred day simple moving average of $1.14.

TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Company Profile

(Get Free Report)

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.

See Also